A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 2
- Sponsors LEO Pharma
- 14 Jul 2017 Status changed from not yet recruiting to recruiting.
- 08 Jun 2017 Planned initiation date changed from 6 Jun 2017 to 28 Jun 2017.
- 24 May 2017 New trial record